Articles

Articles

Archive by tag: healthcareReturn
This month, the Insights Association focused on extensive artificial intelligence legislation at the state level, urgent developments in privacy compliance in California and Washington state, new bills on census issues (including one that would kill the ACS), the insights compliance concerns with sales taxes on SaaS and PaaS, and a couple of new telephone-related bills.
Read More
As we close out an intense summer for the insights industry, the Insights Association has been focused on a wide variety of policy issues, including: the launch of a new program for legally transferring European Union personal data to the U.S.; looming worries in complying with state comprehensive consumer data privacy laws that came into effect on July 1, and newly-passed state laws in Florida and Tennessee; the latest developments in compliance concerns and regulation of artificial intelligenc...
Read More
As temperatures rose, so did the threats and opportunities for the insights industry in advocacy during May, ranging from three new comprehensive state privacy laws, advancing regulation of artificial intelligence, compliance concerns with state sales taxes, jousting over the Census Household Panel, restrictions on high-end incentives for research subjects, state legislation to ban non-competes, and a new Maryland law restricting most telephone calls for research purposes.
Read More
Temperatures may be cooling as the calendar turns to autumn, but legislative issues are heating up as lawmakers get back to work following summer breaks. Here are some of the key issues we're engaged with at the national and state level on your behalf...
Read More
Pennsylvania Rep. Mike Zabel (D-PA-163) reintroduced the Pharmaceutical Manufacturing Prohibited Gifts Act (H.B. 593), adding an amendment recommended by the Insights Association that would protect bona fide marketing research with health care professionals.
Read More
New regulations in New Jersey restricting interactions between medical professionals and pharmaceutical manufacturers should not impede marketing research, thanks to the advocacy of the Insights Association, the leading nonprofit association representing the marketing research and analytics industry.
Read More
A leading research association testified at a hearing in New Jersey on October 19, 2017 about proposed regulations on payments to medical professionals, urging an exemption for pharmaceutical marketing research incentive payments.
Read More
On August 1, 2013, the first reporting period under the Physician Payment Sunshine Act began. Part of the Patient Protection and Affordable Care Act (aka, “Obamacare”), it requires pharmaceutical and medical device manufacturers to publicly report many types of payments made to physicians, which will be public. The Sunshine Act was intended to bring transparency to these relationships, to minimize manufacturers’ influence on physicians’ prescribing behavior.
Read More
Texas governor, Rick Perry, has signed a new health bill, H.B. 300, into law that enforces new obligations in addition to the requirements of the HIPAA privacy rule. The law, which becomes effective September 1, 2012, provides an expansive definition of a covered entity and is likely to include non-covered entities under HIPAA, including survey researchers.
Read More
Pharmaceutical marketing research and data analytics companies should not be required to assume responsibility for formal reporting of adverse events (AEs) uncovered during routine pharmaceutical marketing research and data analytics in the U.S. because:
Read More
Members only Article - Please login to view